Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: A 12-month follow-up study

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Claes, Nele ^a   Dhaeze, Tessa ^a   Fraussen, Judith ^a   Broux, Bieke ^a   Van Wijmeersch, Bart ^a,b   Stinissen, Piet ^a   Hupperts, Raymond ^c,d   Hellings, Niels ^a   Somers, Veerle ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b Rehabilitation and MS Center   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; FINGOLIMOD; PROGRAMMED DEATH 1 RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTE SUBSETS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84910003086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111115     Document Type: Article

References (38)

1. Broux B, Stinissen P, Hellings N (2013) Which immune cells matter? The immunopathogenesis of multiple sclerosis. Crit Rev Immunol 33: 283-306.
2. Fraussen J, Vrolix K, Martinez-Martinez P, Losen M, De Baets MH, et al. (2009) B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev 8: 654-658.
3. Palanichamy A, Apeltsin L, Kuo TC, Sirota M, Wang S, et al. (2014) Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 6: 248ra106.
4. Moser B, Loetscher P (2001) Lymphocyte traffic control by chemokines. Nat Immunol 2: 123-128.
5. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
6. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, et al. (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16: 197-207.
7. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
8. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, et al. (2009) Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72: 73-79.
9. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
10. Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366: 339-347.
11. von Wenckstern H, Zimmermann K, Kleuser B (2006) The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp (Warsz) 54: 239-251.
12. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kumpfel T, et al. (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76: 1214-1221.
13. Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, et al. (2014) Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol 268: 95-98.
14. Nakamura M, Matsuoka T, Chihara N, Miyake S, Sato W, et al. (2014) Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler.
15. Miyazaki Y, Niino M, Fukazawa T, Takahashi E, Nonaka T, et al. (2014) Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clin Immunol 151: 127-135.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
17. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, et al. (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178: 6092-6099.
18. von Budingen HC, Bar-Or A, Zamvil SS (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 23: 713-720.
19. Craft JE (2012) Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 8: 337-347.
20. Weinstein JS, Hernandez SG, Craft J (2012) T cells that promote B-Cell maturation in systemic autoimmunity. Immunol Rev 247: 160-171.
21. Linterman MA, Liston A, Vinuesa CG (2012) T-follicular helper cell differentiation and the co-option of this pathway by non-helper cells. Immunol Rev 247: 143-159.
22. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, et al. (2011) Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17: 983-988.
23. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al. (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71: 1261-1267.
24. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, et al. (2010) Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75: 403-410.
25. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, et al. (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 102: 1045-1050.
26. Han S, Zhang X, Wang G, Guan H, Garcia G, et al. (2004) FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 104: 4129-4133.
27. Boulton C, Meiser K, David OJ, Schmouder R (2012) Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. J Clin Pharmacol 52: 1879-1890.
28. Vora KA, Nichols E, Porter G, Cui Y, Keohane CA, et al. (2005) Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement. J Leukoc Biol 78: 471-480.
29. Cinamon G, Zachariah MA, Lam OM, Foss FW Jr, Cyster JG (2008) Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 9: 54-62.
30. Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, et al. (2004) Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 5: 713-720.
31. Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76: S20-27.
32. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al. (2008) Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89.
33. Venken K, Hellings N, Liblau R, Stinissen P (2010) Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 16: 58-68.
34. Serpero LD, Filaci G, Parodi A, Battaglia F, Kalli F, et al. (2013) Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. J Neuroimmune Pharmacol.
35. Zhou PJ, Wang H, Shi GH, Wang XH, Shen ZJ, et al. (2009) Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. Clin Exp Immunol 157: 40-47.
36. Tellier J, Nutt SL (2013) The unique features of follicular T cell subsets. Cell Mol Life Sci 70: 4771-4784.
37. He J, Tsai LM, Leong YA, Hu X, Ma CS, et al. (2013) Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 39: 770-781.
38. Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, et al. (2011) Antigenspecific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 69: 408-413.